Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2022
- The Future of Generics
Advertise

Search

Search

Close

Trending

Health Innovators – Monique Levy

Deep Dive: Digital Health 2022

ViiV Healthcare study reveals outdated perceptions of HIV

Eisai’s full lecanemab phase 3 trial results for Alzheimer’s presented at CTAD

Expansion of CareQuest partnership with CIPCOH, funding ‘100 Million Mouths’

Affimed

Cancer attacked by T cells 600

News/ News/ Oncology

AACR: Affimed builds case for natural killer cell therapy

Phil Taylor Affimed, bispecific antibody, classical Hodgkin lymphoma, immuno-oncology, natural killer cell, non-Hodgkin lymphoma, Oncology 0 Comment

Affimed says new data from a phase 1/2 trial of its natural killer (NK) cell engager therapy AFM13

X

AACR: Affimed builds case for natural killer cell therapy

https://pharmaphorum.com/news/aacr-affimed-builds-case-for-natural-killer-cell-therapy/

Affimed and Roche ink $5bn plus cancer immunotherapy deal

News/ News/ Oncology/ Top stories

Affimed and Roche ink $5bn plus cancer immunotherapy deal

Richard Staines Affimed, cancer immunotherapy, Genentech, Roche 0 Comment

Deal is based on natural killer cell therapeutics

X

Affimed and Roche ink $5bn plus cancer immunotherapy deal

https://pharmaphorum.com/news/affimed-and-roche-ink-5bn-plus-cancer-immunotherapy-deal/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

Frontiers Health Steering Committee spotlight – Monique Levy

Frontiers Health Steering Committee spotlight – Monique Levy

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Most popular

Most Viewed

AstraZeneca leads winners at Reuters Pharma Awards 2022
Veeva Systems Summit, Madrid - pharmaphorum reflects
Another Twitter blow to science as Musk ends COVID misinformation policy
Genentech withdraws US indication of Tecentriq for bladder, urinary tract cancer
AstraZeneca, MSD raise prostate cancer awareness with 'Never Miss' campaign

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com